These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34405495)

  • 1. Long-term experience using CNI-free immunosuppression in selected paediatric heart transplant recipients.
    Rosenthal LM; Nordmeyer J; Kramer P; Danne F; Pfitzer C; Berger F; Schmitt KRL; Schubert S
    Pediatr Transplant; 2021 Dec; 25(8):e14111. PubMed ID: 34405495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin inhibitor- and corticosteroid-free immunosuppression in pediatric heart transplant patients.
    Sierra CM; Tan R; Eguchi J; Bailey L; Chinnock RE
    Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27658616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empiric switch from calcineurin inhibitor to sirolimus-based immunosuppression in pediatric heart transplantation recipients.
    Loar RW; Driscoll DJ; Kushwaha SS; Cramer CH; O'Leary PW; Daly RC; Mauriello DA; Johnson JN
    Pediatr Transplant; 2013 Dec; 17(8):794-9. PubMed ID: 24164828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with belatacept rescue therapy in kidney transplant recipients.
    Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
    Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
    Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
    Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients.
    Asleh R; Briasoulis A; Kremers WK; Adigun R; Boilson BA; Pereira NL; Edwards BS; Clavell AL; Schirger JA; Rodeheffer RJ; Frantz RP; Joyce LD; Maltais S; Stulak JM; Daly RC; Tilford J; Choi WG; Lerman A; Kushwaha SS
    J Am Coll Cardiol; 2018 Feb; 71(6):636-650. PubMed ID: 29420960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
    Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B
    Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
    Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance immunosuppression in heart transplantation: insights from network meta-analysis of various immunosuppression regimens.
    Ueyama H; Kuno T; Takagi H; Alvarez P; Asleh R; Briasoulis A
    Heart Fail Rev; 2022 May; 27(3):869-877. PubMed ID: 32424550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcineurin-inhibitor free immunosuppression with mycophenolate mofetil and corticosteroids in paediatric renal transplantation improves renal allograft function without increasing acute rejection.
    Krischock L; Gullett A; Bockenhauer D; Rees L; Trompeter RS; Marks SD
    Pediatr Transplant; 2009 Jun; 13(4):475-81. PubMed ID: 18992054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
    Kaplinsky E; González-Costello J; Manito N; Roca J; Barbosa MJ; Nebot M; Salazar-Mendiguchia J; Berdejo J; Mañas P; Miralles A; Cequier A
    Transplant Proc; 2012 Nov; 44(9):2564-6. PubMed ID: 23146455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
    Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
    Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin-inhibitor free immunosuppression after lung transplantation - a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors.
    Gottlieb J; Fischer B; Schupp JC; Golpon H
    PLoS One; 2023; 18(5):e0284653. PubMed ID: 37200246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Sirolimus-based Early Calcineurin Inhibitor Reduction in Liver Transplantation: Impact on Renal Function.
    Buchholz BM; Ferguson JW; Schnitzbauer AA; Nightingale P; Schlitt HJ; Geissler EK; Mirza DF;
    Transplantation; 2020 May; 104(5):1003-1018. PubMed ID: 31577671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Edwards BS; Frantz RP; Daly RC; Lerman A; Kushwaha SS
    J Heart Lung Transplant; 2018 Nov; 37(11):1372-1380. PubMed ID: 30174165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation.
    Asante-Korang A; Carapellucci J; Krasnopero D; Doyle A; Brown B; Amankwah E
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28708333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.